239 related articles for article (PubMed ID: 16288937)
1. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
de Roux A; Marx A; Burkhardt O; Schweiger B; Borkowski A; Banzhoff A; Pletz MW; Lode H
Vaccine; 2006 Mar; 24(10):1537-42. PubMed ID: 16288937
[TBL] [Abstract][Full Text] [Related]
2. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
3. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
Camilloni B; Neri M; Lepri E; Iorio AM
Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
Esposito S; D'Angelo E; Daleno C; Peia F; Scala A; Serra D; Mirra N; Galeone C; Principi N
Vaccine; 2010 Nov; 28(50):7825-8. PubMed ID: 20888873
[TBL] [Abstract][Full Text] [Related]
7. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
8. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
Ansaldi F; Zancolli M; Durando P; Montomoli E; Sticchi L; Del Giudice G; Icardi G
Vaccine; 2010 Jun; 28(25):4123-9. PubMed ID: 20433807
[TBL] [Abstract][Full Text] [Related]
9. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
[TBL] [Abstract][Full Text] [Related]
10. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
11. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
12. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
Ruf BR; Colberg K; Frick M; Preusche A
Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
[TBL] [Abstract][Full Text] [Related]
13. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
14. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
[TBL] [Abstract][Full Text] [Related]
16. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
[TBL] [Abstract][Full Text] [Related]
18. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]